(News Bulletin 247) – AstraZeneca announced on Wednesday the success of a Phase 3 clinical study combining its molecules Imfinzi and Lynparza in the treatment of ovarian cancer.
The trial met its primary endpoint of improving progression-free survival of newly diagnosed patients who do not express the BRCA gene mutation.
AstraZeneca specifies that the study aimed to compare the effectiveness of the combination, in addition to chemotherapy and the administration of Avastin, in comparison with a treatment based only on chemotherapy and Avastin.
According to the pharmaceutical group, this option resulted in a ‘statistically and clinically significant’ improvement in disease progression-free survival.
Ovarian cancer is currently the eighth most common cancer in women, with 314,000 new cases per year and 207,000 annual deaths, figures that are expected to rise to 445,000 and 314,000 respectively by 2040.
On the London Stock Exchange, AstraZeneca shares changed little on Wednesday morning following these announcements and posted a limited gain of around 0.5% at the start of the session.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
